01
Location:
Homepage
/
EGF vaccine Click Click Detailed product introduction

EGF vaccine Click Click Detailed product introduction

EGF vaccine Click Click Detailed product introduction

Jointly developed by BPL and CIM, EGF vaccine (rEGF-p64K/Mont vaccine) is a conjugated peptide vaccine of recombinant human epidermal growth factor (hu-rEGF) produced in beer yeast and recombinant Neisseria meningitidis P64k protein produced in E. coli.  The hu-rEGF-rP64k/Mont vaccine is an active immunotherapy, intended to prevent binding of the endogenous EGF to the receptors, by inducing anti-EGF antibodies that clear the growth factor from circulation. The vaccine inhibits the growth of tumor cells and blood vessels and induces tumor cell apoptosis to antitumor efficacy and improves the patient's survival quality and survival rate. Animal experiments and clinical trials have shown that the curative effect of EGF vaccine is distinct on EGFR overexpression malignant tumor such as lung cancer, head and neck cancer, ovarian cancer, especially for non-small cell lung cancer (NSCLC). The EGF vaccine has been completed seven clinical trials on safety and immunogenicity: 5 phase I clinical trials, 1 phase II clinical trial and 1 phase Ⅲclinical trial.There are 900 patients with NSCLC injected EGF vaccine in worldwide. The vaccination results evidenced the immunogenicity and safety of vaccination in patients.Compared with the historical control group, the patients who have good resistance to EGF reaction had a survival advantage.The EGF vaccine has been approved in Cuba, Peru and Paraguay for treatment of advanced stage NSCLC.In China, phaseⅠclinical trial on advanced NSCLC has been finished, and we plan to carry out phase Ⅱ/Ⅲclinical trial.
服务热线 400-659-2330
Taixinsheng

Jointly developed by BPL and CIM, EGF vaccine (rEGF-p64K/Mont vaccine) is a conjugated peptide vaccine of recombinant human epidermal growth factor (hu-rEGF) produced in beer yeast and recombinant Neisseria meningitidis P64k protein produced in E. coli. 
This product employs specific active immunity to target at the signaling pathway of EGF-EGFR cells. It could effectively prevent and block the signal transduction pathway of tumor cells by producing anti-EGF antibody. This treatment is proved to have great efficacy in treating the tumor of epithelial cell where EGFR is over-expressed, like H&N cancer, ovarian cancer and particularly NSCLC. 
Now EGF vaccine has been approved to treat patients with NSCLC in Cuba, Peru and Paraguay. And BPL has finished Phase I study in China and is planning to conduct Phase II/III study.

搜索

Biotech pharmaceutical co., Ltd

Address:NO.2 Rongjing East Street, Beijing Economic and Technological Development Area, Beijing 100176

Biotech pharmaceutical co., Ltd  京ICP备05019954号 互联网药品信息编号:(京)非经营性2016-0046    www.300.cn